Pro Share Advisors LLC Inhibrx, Inc. Transaction History

Pro Share Advisors LLC

  • $39.7 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
BUY
$32.76 - $39.56 $263,161 - $317,785
8,033 Added 92.25%
16,741 $585,000
Q4 2023

Feb 14, 2024
BUY
$14.5 - $38.0 $126,266 - $330,904
8,708 New
8,708 $330,000
Q2 2022

Aug 01, 2022
SELL
$8.52 - $25.26 $79,005 - $234,235
-9,273 Closed
0 $0
Q1 2022

May 10, 2022
SELL
$19.89 - $43.18 $43,121 - $93,614
-2,168 Reduced 18.95%
9,273 $206,000
Q4 2021

Feb 08, 2022
BUY
$26.75 - $46.02 $306,046 - $526,514
11,441 New
11,441 $500,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email